Literature DB >> 12611462

Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.

Gudrun Pohl1, Margaretha Rudas, Susanne Taucher, Thomas Stranzl, Günther G Steger, Raimund Jakesz, Robert Pirker, Martin Filipits.   

Abstract

Molecular markers predicting response to preoperative chemotherapy would be of major clinical relevance in breast cancer. Therefore, we studied the relationship between the expression of cell cycle regulatory proteins and clinical outcome in breast cancer patients receiving preoperative chemotherapy. Expression of p2lWaf1, p27KiP1, p53, cyclin D3 and Ki-67 was determined in breast carcinomas by means of immunohistochemistry both prior and after preoperative chemotherapy. Expression data were compared with both clinical parameters and response to preoperative chemotherapy with either cyclophosphamide/methotrexate/5-fluorouracil (CMF, n = 29) or epirubicin/docetaxel (ED, n = 36). In paired samples before and after preoperative chemotherapy, the percentage of p21Waf1, p27Kip1, p53 and cyclin D3 positive nuclei of tumor cells in postchemotherapy specimens was significantly higher than the percentage in prechemotherapy samples but no change in Ki-67 expression was observed. High Ki-67 expression (p = 0.02), negative estrogen receptor status (p = 0.01) and negative progesterone receptor status (p = 0.04) were associated with complete pathologic response to chemotherapy, whereas the other markers did not predict response. In conclusion, expression levels of p21Waf1, p27Kip1, p53 and cyclin D3 significantly increased after preoperative chemotherapy in breast carcinomas but only high Ki-67 expression, negative estrogen receptor status and negative progesterone receptor status were associated with complete pathologic response to preoperative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611462     DOI: 10.1023/a:1022165715043

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.

Authors:  András Vörös; Erika Csörgő; Bence Kővári; Péter Lázár; Gyöngyi Kelemen; Orsolya Rusz; Tibor Nyári; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

2.  HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.

Authors:  Norbert Arens; Uwe Bleyl; Ralf Hildenbrand
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

3.  The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.

Authors:  An Sen Tan; Joe Poe Sheng Yeong; Chi Peng Timothy Lai; Chong Hui Clara Ong; Bernett Lee; Jeffrey Chun Tatt Lim; Aye Aye Thike; Jabed Iqbal; Rebecca Alexandra Dent; Elaine Hsuen Lim; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2019-08-12       Impact factor: 4.064

4.  Effect of indomethacin on cell cycle proteins in colon cancer cell lines.

Authors:  Mei-Hua Xu; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

5.  Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.

Authors:  Madhu Sudhan Shaik; Abhijit Chatterjee; Tanise Jackson; Mandip Singh
Journal:  Int J Cancer       Date:  2006-01-15       Impact factor: 7.396

6.  BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.

Authors:  Katerina Bouchalova; Marek Svoboda; Gvantsa Kharaishvili; Jana Vrbkova; Jan Bouchal; Radek Trojanec; Vladimira Koudelakova; Lenka Radova; Karel Cwiertka; Marian Hajduch; Zdenek Kolar
Journal:  Tumour Biol       Date:  2015-01-24

7.  Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.

Authors:  Ksenija Kanjer; Svetislav Tatić; Zora Nešković-Konstantinović; Zaki Abu Rabi; Dragica Nikolić-Vukosavljević
Journal:  Pathol Oncol Res       Date:  2013-03-24       Impact factor: 3.201

8.  Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.

Authors:  Charles Lemarignier; Frédéric Di Fiore; Charline Marre; Sébastien Hapdey; Romain Modzelewski; Pierrick Gouel; Pierre Michel; Bernard Dubray; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-19       Impact factor: 9.236

9.  Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.

Authors:  Yuri Takahashi; Yasuo Miyoshi; Koji Morimoto; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-13       Impact factor: 4.322

10.  The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines.

Authors:  Marike Gabrielson; Elisabet Tina
Journal:  Oncol Rep       Date:  2013-01-23       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.